Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

Concetta Crivera, Cherilyn DeSouza, Chris M Kozma, Riad D Dirani, Lian Mao, Wayne Macfadden, Concetta Crivera, Cherilyn DeSouza, Chris M Kozma, Riad D Dirani, Lian Mao, Wayne Macfadden

Abstract

Background: Schizophrenia is a chronic mental health disorder associated with increased hospital admissions and excessive utilization of outpatient services and long-term care. This analysis examined health care resource utilization from a 24-month observational study of patients with schizophrenia initiated on risperidone long-acting therapy (RLAT).

Methods: Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE) was a 24-month observational study designed to examine real-world treatment outcomes by prospectively following patients with schizophrenia initiated on RLAT. At baseline visit, prior hospitalization and ER visit dates were obtained for the previous 12 months and subsequent hospitalization visit dates were obtained at 3-month visits, if available. The health care resource utilization outcomes measures observed in this analysis were hospitalizations for any reason, psychiatric-related hospitalizations, and emergency room (ER) visits. Incidence density analysis was used to assess pre-event and postevent rates per person-year (PY).

Results: The primary medical resource utilization analysis included 435 patients who had a baseline visit, ≥1 postbaseline visits after RLAT initiation, and valid hospitalization dates. The number of hospitalizations and ER visits per PY declined significantly (p < .0001) after initiation with RLAT. A 41% decrease (difference of -0.29 hospitalizations per PY [95% CI: -0.39 to -0.18] from baseline) in hospitalizations for any reason, a 56% decrease (a difference of -0.35 hospitalizations per PY [95% CI: -0.44 to -0.26] from baseline) in psychiatric-related hospitalizations, and a 40% decrease (-0.26 hospitalizations per PY [95% CI: -0.44 to -0.10] from baseline) in ER visits were observed after the baseline period. The percentage of psychiatric-related hospitalizations decreased significantly after RLAT initiation, and patients had fewer inpatient hospitalizations and ER visits (all p < .0001).

Conclusion: The results suggest that treatment with RLAT may result in decreased hospitalizations for patients with schizophrenia.

Trial registration: ClinicalTrials.gov: NCT00246194.

Figures

Figure 1
Figure 1
Change from Baseline in Hospitalization Incidence Rate. (pre-RLAT versus post-RLAT period [n = 435; p < .01 for all]).
Figure 2
Figure 2
Percentage of patients with >1 psychiatric-related hospitalization. (n = 343; p < .0001).

References

    1. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66:1122–1129. doi: 10.4088/JCP.v66n0906.
    1. Wyatt RJ, Henter I, Leary MC, Taylor E. An economic evaluation of schizophrenia--1991. Soc Psychiatry Psychiatr Epidemiol. 1995;30(5):196–205.
    1. Kim B, Lee SH, Choi TK, Suh S, Kim YW, Lee E, Yook KH. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1231–1235. doi: 10.1016/j.pnpbp.2008.03.012.
    1. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007;23(10):2305–2312. doi: 10.1185/030079907X226050.
    1. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125–1132. doi: 10.1176/appi.ajp.160.6.1125.
    1. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, Pretorius H, David AS. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111–117. doi: 10.1016/j.euroneuro.2004.07.003.
    1. Fleischhacker W, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O. Treatment of schizophrenia with long acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003;64:1250–1257. doi: 10.4088/JCP.v64n1017.
    1. Ehret MJ, Fuller MA. Long-acting injectable risperidone. Ann Pharmacother. 2004;38(12):2122–2127. doi: 10.1345/aph.1E085.
    1. Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, Eriksson L, Smeraldi E. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35:2367–2377. doi: 10.1038/npp.2010.111. [published correction appears in Neuropsychopharmacology. 2011, 36:548]
    1. Conley RR, Kelly DL, Love RC, McMahon RP. Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry. 2003;15(1):23–31.
    1. Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am J Health Syst Pharm. 1998;55(Suppl 2):S17–S19. 1998.
    1. Fuller M, Shermock K, Russo P, Secic M, Dirani R, Vallow S, Flanders S. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ. 2009;12:317–324. doi: 10.3111/13696990903303902.
    1. RISPERDAL® CONSTA® [Package Insert] Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2009.
    1. Macfadden W, DeSouza C, Crivera C, Kozma CM, Dirani RD, Mao L, Rodriguez SC. Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results. BMC Psychiatry. p. 167.
    1. Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A. e-STAR Study Group. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the eSTAR database in Spain. Appl Health Econ Health Policy. 2008;6:41–53. doi: 10.2165/00148365-200806010-00004.
    1. Taylor M, Currie A, Lloyd K, Price M, Peperell K. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmcol. 2008;22:128–131. doi: 10.1177/0269881107084068.
    1. Leal A, Rosillon D, Mehnert A, Jarema M, Remington G. Health resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf. 2004;13:811–816. doi: 10.1002/pds.978.
    1. Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand. 2006;114:14–20. doi: 10.1111/j.1600-0447.2006.00766.x.
    1. Spill B, Konoppa S, Kissling W, Maino K, Messer T, Heres S. Long-term observation of patients successfully switched to risperidone long-acting injectable: A retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. Int J Psychiatry Clin Pract. 2010;14:53–62. doi: 10.3109/13651500903311821.
    1. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand. 2007;116:36–46. doi: 10.1111/j.1600-0447.2006.00980.x.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner